The use of antisepses in cancer therapy is growing, with some of the latest data suggesting the drugs can reduce cancer’s growth rate.
But new data published in the Journal of Cancer Research suggests that these drugs don’t actually help.
What’s new in this article: A new analysis of the data by researchers at the University of Cambridge and the University College London suggests that there is no evidence that the antiseptic drug Nabilone reduces cancer growth.
The authors argue that “the clinical and research literature has demonstrated that Nabilones use in cancer treatment has limited clinical efficacy, even in the highest-quality clinical trials” and they suggest that further studies on the drug are needed to see if this is true in the clinic.
The authors note that, in the U.S., there is a “consistent trend towards the use of the anti-cancer drug Nafcillin for treatment of cancer”, but this is not the case in the UK, where there is “limited evidence that Nafcilin reduces cancer progression and survival”.
The researchers conclude that there are “no indications that NAFcillin is a useful drug for cancer therapy”.
The researchers write:”This is a worrying conclusion given that the drug is approved for use in the NHS, which may be responsible for the lack of efficacy observed in clinical trials.”
The authors of the study, who have published before, said they were concerned about the lack for evidence to back up their claims.
“The use of anti-parasitic drugs for cancer treatment is becoming more and more prevalent.
This means that the use and regulation of anti–cancer therapies will be challenged,” they write.”
This has a significant impact on the overall effectiveness of cancer therapies.
The paper is the latest in a series of papers that have highlighted the problems with antisephesis treatments. “
Given that there has been little evidence to support the use or efficacy of antispeptic drugs in cancer, it is critical that researchers and clinicians continue to pursue their investigations in this area.”
The paper is the latest in a series of papers that have highlighted the problems with antisephesis treatments.
Last year, the British Cancer Society published an analysis of data from more than a dozen trials of antiparasites.
It concluded that there was “no evidence that anti-Parasite treatments are effective in preventing or reversing cancer progression, and that they may be associated with a variety of adverse events, including increased mortality and increased costs”.
Earlier this year, a study published in The Lancet journal suggested that antiinflammatory drugs may be more effective at treating certain types of cancer than other types.